{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T15:10:02Z","timestamp":1759849802994,"version":"build-2065373602"},"reference-count":20,"publisher":"BMJ","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Heart"],"published-print":{"date-parts":[[2009,4]]},"DOI":"10.1136\/hrt.2008.163345","type":"journal-article","created":{"date-parts":[[2009,1,27]],"date-time":"2009-01-27T22:28:32Z","timestamp":1233095312000},"page":"522-523","source":"Crossref","is-referenced-by-count":19,"title":["Dopamine agonist therapy for hyperprolactinaemia and cardiac valve dysfunction; a lot done but much more to do"],"prefix":"10.1136","volume":"95","author":[{"given":"Mark","family":"Sherlock","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andy A","family":"Toogood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Steeds","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2009,1,27]]},"reference":[{"key":"2025100707180312000_95.7.522.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)15945-X"},{"key":"2025100707180312000_95.7.522.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(03)00049-4"},{"key":"2025100707180312000_95.7.522.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062222"},{"key":"2025100707180312000_95.7.522.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa054830"},{"key":"2025100707180312000_95.7.522.5","unstructured":"US Food and Drug Administration . FDA announces voluntary withdrawal of pergolide products. FDA bulletin. http:\/\/www.fda.gov\/bbs\/topics\/NEWS\/2007\/NEW01596.html, 29 March 2007."},{"key":"2025100707180312000_95.7.522.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp068265"},{"key":"2025100707180312000_95.7.522.7","doi-asserted-by":"publisher","DOI":"10.1124\/mol.63.6.1223"},{"key":"2025100707180312000_95.7.522.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2006.08.004"},{"key":"2025100707180312000_95.7.522.9","doi-asserted-by":"publisher","DOI":"10.1210\/er.2007-0041"},{"key":"2025100707180312000_95.7.522.10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)04006-X"},{"key":"2025100707180312000_95.7.522.11","unstructured":"Medicines and Healthcare Products Regulatory Authority . www.mhra.gov.uk\/home\/idcplg?IdcService\u200a=\u200aGET_FILE&dDocName\u200a=\u200aCON028266&RevisionSelectionMethod\u200a=\u200aLatest . 2008. (Accessed 20 November 2008.)"},{"key":"2025100707180312000_95.7.522.12","unstructured":"Medicines and Healthcare Products Regulatory Authority . www.mhra.gov.uk\/home\/idcplg?IdcService\u200a=\u200aGET_FILE&dDocName\u200a=\u200aCON028263&RevisionSelectionMethod\u200a=\u200aLatest . 2008. (Accessed 20 November 2008.)"},{"key":"2025100707180312000_95.7.522.13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2008.01779.x"},{"key":"2025100707180312000_95.7.522.14","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2007-1403"},{"key":"2025100707180312000_95.7.522.15","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2007-2658"},{"key":"2025100707180312000_95.7.522.16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1530\/EJE-08-0213","article-title":"Cabergoline and the risk of valvular lesions in endocrine disease.","volume":"159","author":"Lancellotti","year":"2008","journal-title":"Eur J Endocrinol Eur Fed Endocr Soc"},{"key":"2025100707180312000_95.7.522.17","doi-asserted-by":"crossref","unstructured":"Vallette S Serri K Rivera J . Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas. Pituitary 2008 Jul 2 [Epub ahead of print].","DOI":"10.1007\/s11102-008-0134-2"},{"key":"2025100707180312000_95.7.522.18","doi-asserted-by":"crossref","first-page":"R11","DOI":"10.1530\/EJE-08-0365","article-title":"Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease.","volume":"159","author":"Wakil","year":"2008","journal-title":"Eur J Endocrinol Eur Fed Endocr Soc"},{"key":"2025100707180312000_95.7.522.19","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1530\/EJE-08-0611","article-title":"Cabergoline and cardiac valve disease in prolactinoma patients: additional studies during long-term treatment are required.","volume":"159","author":"Kars","year":"2008","journal-title":"Eur J Endocrinol Eur Fed Endocr Soc"},{"key":"2025100707180312000_95.7.522.20","doi-asserted-by":"publisher","DOI":"10.1016\/S0894-7317(03)00335-3"}],"container-title":["Heart"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/hrt.2008.163345","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T14:29:47Z","timestamp":1759847387000},"score":1,"resource":{"primary":{"URL":"https:\/\/heart.bmj.com\/lookup\/doi\/10.1136\/hrt.2008.163345"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1,27]]},"references-count":20,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2009,3,13]]},"published-print":{"date-parts":[[2009,4]]}},"alternative-id":["10.1136\/hrt.2008.163345"],"URL":"https:\/\/doi.org\/10.1136\/hrt.2008.163345","relation":{},"ISSN":["1355-6037","1468-201X"],"issn-type":[{"type":"print","value":"1355-6037"},{"type":"electronic","value":"1468-201X"}],"subject":[],"published":{"date-parts":[[2009,1,27]]}}}